Sirnaomics Presents Preclinical HPV Data | GenomeWeb

Sirnaomics this week released preclinical data showing that two siRNAs against different strains of human papillomavirus could halt growth of papillomas in an animal model of HPV infection.

According to the company, siRNAs against HPV16 and HPV18, formulated with histidine-lysine co-polymer into nanoparticles, were delivered topically to a rabbit skin papilloma model challenged by chimeric human-rabbit papillomavirus and inhibited papilloma growth.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.